metformin has been researched along with Hyperuricemia in 8 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High uric acid (HUA) is associated with insulin resistance (IR) in cardiomyocytes." | 8.02 | Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. ( Chen, Y; Jiao, Z; Li, Y; Li, Z; Xie, Y, 2021) |
| " Current data suggest that the mechanism of action of metformin contributes to the development of an anti-inflammatory effect, as well as a decrease in the level of uric acid, and its use can be potentially useful in patients with hyperuricemia and gout." | 4.02 | [Advantages of the use of metformin in patients with impaired uric acid metabolism]. ( Eliseev, MS; Nasonov, EL; Panevin, TS; Zhelyabina, OV, 2021) |
| "High uric acid (HUA) is associated with insulin resistance (IR) in cardiomyocytes." | 4.02 | Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. ( Chen, Y; Jiao, Z; Li, Y; Li, Z; Xie, Y, 2021) |
| "Metformin is always used as the baseline antidiabetic therapy for patients with type 2 diabetes mellitus (T2DM) and hyperuricemia." | 3.91 | Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies. ( Ma, Y; Rao, Z; Sun, X; Wu, X; Xi, D; Zhang, G, 2019) |
| "We report three Caucasian patients affected by gout and type 2 diabetes, who were treated with the recombinant nonglycosylated human interleukin-1 receptor antagonist anakinra (100 mg/day subcutaneously) after an unsatisfactory or incomplete response to urate-lowering therapy, colchicine, nonsteroidal anti-inflammatory drugs, and prednisone." | 3.81 | Anakinra treatment in patients with gout and type 2 diabetes. ( Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eliseev, MS | 1 |
| Panevin, TS | 1 |
| Zhelyabina, OV | 1 |
| Nasonov, EL | 1 |
| Su, M | 1 |
| Sun, L | 1 |
| Li, W | 1 |
| Liu, H | 1 |
| Liu, Y | 1 |
| Wei, Y | 1 |
| Yuan, Y | 1 |
| Zheng, L | 1 |
| Yin, S | 1 |
| Dai, C | 1 |
| Zhao, C | 1 |
| Pan, Z | 1 |
| Li, Y | 2 |
| Tao, T | 1 |
| Yang, Y | 1 |
| Hu, Z | 1 |
| Jiao, Z | 1 |
| Chen, Y | 1 |
| Xie, Y | 1 |
| Li, Z | 1 |
| Zhang, G | 1 |
| Ma, Y | 1 |
| Xi, D | 1 |
| Rao, Z | 1 |
| Sun, X | 1 |
| Wu, X | 1 |
| Nishizawa, K | 1 |
| Yoda, N | 1 |
| Morokado, F | 1 |
| Komori, H | 1 |
| Nakanishi, T | 1 |
| Tamai, I | 1 |
| Ayub, M | 1 |
| Gul, S | 1 |
| Zehra, F | 1 |
| Vitale, A | 1 |
| Cantarini, L | 1 |
| Rigante, D | 1 |
| Bardelli, M | 1 |
| Galeazzi, M | 1 |
8 other studies available for metformin and Hyperuricemia
| Article | Year |
|---|---|
[Advantages of the use of metformin in patients with impaired uric acid metabolism].
Topics: Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Gout; Humans; Hyperuricemia; Hypoglycemic Agent | 2021 |
Metformin alleviates hyperuricaemia-induced serum FFA elevation and insulin resistance by inhibiting adipocyte hypertrophy and reversing suppressed white adipose tissue beiging.
Topics: 3T3-L1 Cells; Adenylate Kinase; Adipocytes; Adipose Tissue, Beige; Adipose Tissue, White; Adult; Ani | 2020 |
A novel HNF1B mutation p.R177Q in autosomal dominant tubulointerstitial kidney disease and maturity-onset diabetes of the young type 5: A pedigree-based case report.
Topics: Aftercare; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Hepatocyte Nuc | 2020 |
Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Cells, Cultured; Glucose; Glucose Transporter Type 4; | 2021 |
Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies.
Topics: Animals; Antiporters; Cell Line; Humans; Hyperuricemia; Hypoglycemic Agents; Kidney; Liver; Male; Me | 2019 |
Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Topics: Adenine; Animals; Antiporters; Cephalexin; Creatinine; Disease Models, Animal; Down-Regulation; Huma | 2019 |
Report: Metformin potential in predisposing arthralgia, type II cross reactivity secondary to group A streptococcus infection & other comorbidities in treating PCOS.
Topics: Analgesics; Arthralgia; Drug Hypersensitivity; Female; Humans; Hyperuricemia; Metformin; Migraine Di | 2019 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; | 2015 |